Swiss biopharmaceutical company developing and commercializing clinical-stage medicines for unmet needs in psychiatry and neurology
Swiss biopharmaceutical company developing and commercializing clinical-stage medicines for unmet needs in psychiatry and neurology. Its pipeline included six compounds sourced through partnerships with Roche, Novartis, and Syngenta, including marketed drugs being evaluated for new indications such as anxiety and Parkinson's disease.